AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia cells, AKT upregulation-induced ROS production attenuated the anticancer effects of imatinib by enriching progenitor cells, which in turn affected susceptibility of the target therapy [52].